We are committed to making a major contribution in efforts to eliminate malaria as a public health threat, particularly in our region.
One of the leading causes of mortality and morbidity globally, malaria was responsible for more than 627,000 deaths, and 241 million clinical cases in 2020 – an increase of 12% compared to the previous year, according the WHO’s latest World Malaria Report. An estimated 2.5 billion people are at risk of the disease, with young children and pregnant women most affected.
A two-way pipeline will be created where our research discoveries can be tested in the field, and field programs inform discovery research through our long-standing connections with vulnerable target populations, especially in Papua New Guinea and Myanmar.
Through this program, Burnet will contribute to:
reaching the WHO elimination targets of a 90 percent reduction in malaria incidence and mortality through an active program of basic, discovery and translational research and in-field education, prevention and treatment programs.
supporting country programs in our region that assist WHO in reaching targets of elimination in at least 35 countries by 2030.
Discover more about Burnet’s malaria work in Episode 8 of our How Science Matters podcast.
Antibody engineering to study responses mediating protective immunity
Clinical studies on malaria
Decision science using Optima
Developing new antimalarial drugs that block protein trafficking
Developing vaccines against malaria
Discovering the mechanisms and targets of immunity against malaria
Evaluating a highly sensitive rapid malaria diagnostic in PNG
Evaluation of Malaria Case-Based Reporting using a mobile phone application in Myanmar
Host and parasite factors that predict Artemisinin Resistance reservoirs
Host red blood cell modification sustains the virulence of malaria parasites
Immunity to malaria and infectious diseases during pregnancy
Immunity, drug efficacy and spread of antimalarial drug resistance
Impact of declining transmission on immunity and risk of malaria rebound
Major advances in understanding malaria immunity and biology
Mechanism of antimalarial drug action
NATNAT: Newly Adapted Tools and Network Against Mosquito Borne Disease Transmission
Optima Malaria Modelling
Optimal community-delivered malaria elimination models for the Greater Mekong Sub-region
Predicting quality and potency of monoclonal and natural antibodies
Serological surveillance to identify mosquito exposure and malaria transmission
Stellabody® Technology in Infectious Disease – COVID-19 and beyond
STRIVE PNG: Stronger Surveillance and Systems Support for Rapid Identification and Containment of Resurgent or Resistant Vector-Borne Pathogens in Papua New Guinea
Vaccines against Plasmodium vivax and P. falciparum malaria
The second half of 2022 saw Burnet launch its 2030 strategy, and continue important work in life sciences, public health and international development.
As the third year of the pandemic got underway, Burnet continued its COVID-19 advocacy around a vaccines plus approach and advanced important work in malaria, tuberculosis and hepatitis C.
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present. We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
Oops!
It looks like something may have gone wrong, and some of the resources required to load the page may not have loaded correctly.